Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center-Reference-Cited by-同舟云学术

Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center

Published:2022 Issue:4 Volume:5 Page:630
ISSN:2590-3233
Container-title:Cancer Research, Statistics, and Treatment
language:en
Short-container-title:Cancer Res Stat Treat

Author:

Prabhash Kumar,Sarma RupJ,Patil VijayM,Shetty Alok,Menon Nandini,Noronha Vanita

Publisher

Medknow

Subject

Cancer Research,Oncology (nursing),Drug Guides,Ophthalmology

Reference24 articles.

1. Head and neck cancers in India;Dandekar;J Surg Oncol,2017

2. Demography and pattern of care of patients with head-and-neck carcinoma: Experience from a tertiary care center in North India;Roy;Cancer Res Stat Treat,2020

3. Impact of demographic factors on delayed presentation of oral cancers: A questionnaire-based cross-sectional study from a rural cancer center;Singla;Cancer Res Stat Treat,2022

4. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study;Burtness;Lancet,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment challenges in developing nations for patients with locally advanced or metastatic head-and-neck cancer;Cancer Research, Statistics, and Treatment;2023

2. Authors’ reply to Khadela et al.;Cancer Research, Statistics, and Treatment;2023

3. Are we spoiled for choice in advanced squamous cell carcinoma of the head-and-neck?;Cancer Research, Statistics, and Treatment;2022